These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 19444077)
1. Large cell carcinoma of the lung: an endangered species? Pardo J; Martinez-Peñuela AM; Sola JJ; Panizo A; Gúrpide A; Martinez-Peñuela JM; Lozano MD Appl Immunohistochem Mol Morphol; 2009 Oct; 17(5):383-92. PubMed ID: 19444077 [TBL] [Abstract][Full Text] [Related]
2. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Mukhopadhyay S; Katzenstein AL Am J Surg Pathol; 2011 Jan; 35(1):15-25. PubMed ID: 21164283 [TBL] [Abstract][Full Text] [Related]
3. Histopathologic classification of lung cancer: Relevance of cytokeratin and TTF-1 immunophenotyping. Johansson L Ann Diagn Pathol; 2004 Oct; 8(5):259-67. PubMed ID: 15494931 [TBL] [Abstract][Full Text] [Related]
4. Thyroid transcription factor 1 and cytokeratins 1, 5, 10, 14 (34betaE12) expression in basaloid and large-cell neuroendocrine carcinomas of the lung. Sturm N; Lantuéjoul S; Laverrière MH; Papotti M; Brichon PY; Brambilla C; Brambilla E Hum Pathol; 2001 Sep; 32(9):918-25. PubMed ID: 11567220 [TBL] [Abstract][Full Text] [Related]
5. TTF-1, cytokeratin 7, 34betaE12, and CD56/NCAM immunostaining in the subclassification of large cell carcinomas of the lung. Rossi G; Marchioni A; Milani M; Scotti R; Foroni M; Cesinaro A; Longo L; Migaldi M; Cavazza A Am J Clin Pathol; 2004 Dec; 122(6):884-93. PubMed ID: 15595193 [TBL] [Abstract][Full Text] [Related]
6. Optimal combination of immunohistochemical markers for subclassification of non-small cell lung carcinomas: A tissue microarray study of poorly differentiated areas. Noh S; Shim H Lung Cancer; 2012 Apr; 76(1):51-5. PubMed ID: 21978426 [TBL] [Abstract][Full Text] [Related]
7. Pulmonary large cell carcinoma lacking squamous differentiation is clinicopathologically indistinguishable from solid-subtype adenocarcinoma. Hwang DH; Szeto DP; Perry AS; Bruce JL; Sholl LM Arch Pathol Lab Med; 2014 May; 138(5):626-35. PubMed ID: 23738762 [TBL] [Abstract][Full Text] [Related]
8. Defective expression of transforming growth factor beta type II receptor (TGFBR2) in the large cell variant of non-small cell lung carcinoma. Xu JB; Bao Y; Liu X; Liu Y; Huang S; Wang JC Lung Cancer; 2007 Oct; 58(1):36-43. PubMed ID: 17566598 [TBL] [Abstract][Full Text] [Related]
9. Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology. Rossi G; Mengoli MC; Cavazza A; Nicoli D; Barbareschi M; Cantaloni C; Papotti M; Tironi A; Graziano P; Paci M; Stefani A; Migaldi M; Sartori G; Pelosi G Virchows Arch; 2014 Jan; 464(1):61-8. PubMed ID: 24221342 [TBL] [Abstract][Full Text] [Related]
10. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Terry J; Leung S; Laskin J; Leslie KO; Gown AM; Ionescu DN Am J Surg Pathol; 2010 Dec; 34(12):1805-11. PubMed ID: 21107086 [TBL] [Abstract][Full Text] [Related]
11. Analysis of clinical characteristics and differential diagnosis of the lung biopsy specimens in 99 adenocarcinoma cases and 111 squamous cell carcinoma cases: utility of an immunohistochemical panel containing CK5/6, CK34βE12, p63, CK7 and TTF-1. Xu XY; Yang GY; Yang JH; Li J Pathol Res Pract; 2014 Oct; 210(10):680-5. PubMed ID: 25063315 [TBL] [Abstract][Full Text] [Related]
12. Best immunohistochemical panel in distinguishing adenocarcinoma from squamous cell carcinoma of lung: tissue microarray assay in resected lung cancer specimens. Kim MJ; Shin HC; Shin KC; Ro JY Ann Diagn Pathol; 2013 Feb; 17(1):85-90. PubMed ID: 23040737 [TBL] [Abstract][Full Text] [Related]
13. [Expression of TTF-1, NapsinA, P63, CK5/6 in Lung Cancer and Its Diagnostic Values for Histological Classification]. Yu H; Li L; Liu D; Li WM Sichuan Da Xue Xue Bao Yi Xue Ban; 2017 May; 48(3):336-341. PubMed ID: 28616902 [TBL] [Abstract][Full Text] [Related]
14. Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3, S100A2, S100A7, and Sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the Lung. Tsuta K; Tanabe Y; Yoshida A; Takahashi F; Maeshima AM; Asamura H; Tsuda H J Thorac Oncol; 2011 Jul; 6(7):1190-9. PubMed ID: 21623236 [TBL] [Abstract][Full Text] [Related]
15. p63 immunostaining in destained bronchoscopic cytological specimens. Shtilbans V; Szporn AH; Wu M; Burstein DE Diagn Cytopathol; 2005 Apr; 32(4):198-203. PubMed ID: 15754365 [TBL] [Abstract][Full Text] [Related]
16. The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas. Kargi A; Gurel D; Tuna B Appl Immunohistochem Mol Morphol; 2007 Dec; 15(4):415-20. PubMed ID: 18091384 [TBL] [Abstract][Full Text] [Related]
17. The Diagnostic Value of TTF-1, P63, HMWK, CK7, and CD56 Immunostaining in the Classification of Lung Carcinoma. Jafarian AH; Gharib M; Mohammadian Roshan N; Sherafatnia S; Omidi AA; Bagheri S Iran J Pathol; 2017; 12(3):195-201. PubMed ID: 29531543 [TBL] [Abstract][Full Text] [Related]
18. Large cell carcinoma of the lung: a tumor in search of an author. A clinically oriented critical reappraisal. Pelosi G; Barbareschi M; Cavazza A; Graziano P; Rossi G; Papotti M Lung Cancer; 2015 Mar; 87(3):226-31. PubMed ID: 25620799 [TBL] [Abstract][Full Text] [Related]
20. p63 and TTF-1 immunostaining. A useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung. Wu M; Wang B; Gil J; Sabo E; Miller L; Gan L; Burstein DE Am J Clin Pathol; 2003 May; 119(5):696-702. PubMed ID: 12760288 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]